Supplementary Figure 4 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial

Key Points

MAIN FINDING: PD-L1 expression significantly correlates with progression free survival in high-grade serous ovarian cancer.
KEY EVIDENCE: Varying PD-L1 scores within treatment arms demonstrate differing survival rates among patients.
APPROACH: Analysis utilized tubo-ovarian samples from the NeoPembrOV/GINECO phase II randomized trial.
SIGNIFICANCE: Findings may influence treatment decisions and enhance understanding of ovarian cancer therapy.

Randomized trial showed progression free survival varies by treatment arm and PD-L1 score in ovarian cancer, suggesting implications for therapy.

Supplementary Figure 4. Progression free survival according to treatment arm and PD-L1 score assessed on tubo-ovarian samples.

No takes yet. Share an insight, caveat, or question.

Collet et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share